摘要
白细胞介素17(IL-17)家族在银屑病的发病过程中发挥重要作用,IL-17A受体拮抗剂能够抑制IL-17的活性。布罗达单抗为一种人源化免疫球蛋白G抗体,对IL-17A受体具有较高的亲和力,能够抑制IL-17所致的炎症反应,在日本已经被批准用于银屑病的治疗。患者对布罗达单抗具有较好的耐受性,最常见的不良事件主要包括鼻咽炎、腹泻、上呼吸道感染等。
The interleukin-17 （IL-17） family plays a central role in the pathogenesis of psoriasis. Blockade of the IL- 17 receptor A （IL- 17RA） inhibits the activity of the IL- 17. Brodalumab is a human monoclonal iinmunoglobulin G antibody which can bind with high affinity to IL-17RA, thereby inhibiting several pro-inflammatory cytokines from the IL-17 family. Brodalumab has been approved in Japan for the treatment of psoriasis. Subcutaneous brodalumab is generally well tolerated in patients with psoriasis. The most common adverse events are nasopharyngitis, diarrhea, upper respiratory tract inflammation and so on.
出处
《中国新药与临床杂志》
CSCD
北大核心
2017年第5期262-264,共3页
Chinese Journal of New Drugs and Clinical Remedies
